Please login to the form below

Not currently logged in
Email:
Password:

PARP inhibitor

This page shows the latest PARP inhibitor news and features for those working in and with pharma, biotech and healthcare.

Pfizer claims rapid FDA nod for Lorbrena

Pfizer claims rapid FDA nod for Lorbrena

inhibitor. “Over the years, Pfizer has transformed research, management and treatment for patients with ALK-positive non-small cell lung cancer. ... It’s the third approval in three months for Pfizer’s oncology unit after having seen success with

Latest news

  • AZ and Clovis PARP inhibitors show their mettle at ESMO AZ and Clovis PARP inhibitors show their mettle at ESMO

    extend its lead over its PARP inhibitor rivals, Tesaro's Zejula (niraparib) and Clovis' Rubraca (rucaparib). ... nivolumab) in ‘all-comer’first-line ovarian cancer, attempting to extend the use of its PARP inhibitor beyond BRCA-positive patients.

  • A look ahead to key trial readouts at ESMO A look ahead to key trial readouts at ESMO

    The highlights of the targeted cancer therapy track include the SOLO-1 trial of AstraZeneca’s PARP inhibitor Lynparza (olaparib) as a maintenance treatment for BRCA1/2-mutated ovarian cancer, and ... VEGF/FGF/PDGF inhibitor will give an update on

  • AZ nabs US approval for new leukaemia drug Lumoxiti AZ nabs US approval for new leukaemia drug Lumoxiti

    of targeted cancer drugs, along with BTK inhibitor Calquence (acalabrutinib) for B-cell malignancies which picked up its first approval last year. ... cancer. However, AZ has two other targeted drugs – PARP inhibitor Lynparza (olaparib) for breast and

  • DNA damage specialists Artios Pharma raises $84m DNA damage specialists Artios Pharma raises $84m

    While many were initially sceptical about the clinical and commercial potential of the first generation DDR drugs, the PARP inhibitor class which Lynparza belongs to, their growing commercial success means confidence ... DDR is an exciting field of

  • China’s BeiGene raises $903m from Hong Kong IPO China’s BeiGene raises $903m from Hong Kong IPO

    cancer (NSCLC), hepatocellular carcinoma, and oesophageal squamous cell carcinoma, the company is developing BTK inhibitor zanubrutinib and pamiparib, a PARP 1/2 inhibitor. ... It’s a potential rival to marketed PARP inhibitors from AstraZeneca

More from news
Approximately 1 fully matching, plus 68 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare

    for Lynparza, the first in class PARP inhibitor now approved in ovarian and breast cancers.

  • Deal Watch August 2016 Deal Watch August 2016

    The lead product is talazoparib, a PARP inhibitor, bought from BioMarin in phase III for treatment of BRCA mutated advanced breast cancer. ... 540. MEI Pharma (US). Helsinn (CH). Licence. Pracinostat, phase III-ready HDAC inhibitor for treatment of acute

  • Deal Watch April 2016 Deal Watch April 2016

    3, 340. Nimbus Apollo (US). Gilead (US). Company acquisition. Phase I Acetyl-CoA Carboxylase (ACC) inhibitor programme for live disease. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP inhibitor in clinical phase for

  • Pharma deals in August 2015 Pharma deals in August 2015

    Looking at another combination, AstraZeneca entered into a clinical trial collaboration this time with durvalumab in combination with Mirati Therapeutics' investigational spectrum-selective histone deacetylase (HDAC) inhibitor, mocetinostat.

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    EGFR-TK) inhibitor, which has so far been approved in non-small cell lung cancer, albeit after a much-delayed, stop-start regulatory journey. ... The former is a PARP inhibitor currently under review in both the EU and the US for ovarian cancer, while AZ

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics